Thiazolidinedione compounds: a patent review (2010 - present).

Introduction: The prevalence of metabolic syndrome, obesity and insulin resistance has become an epidemic. Thiazolidinediones (TZDs) affect glucose and lipid metabolism in insulin-sensitive tissues, which in turn reduces the lipid content in the liver by modulating several mediators. TZD as a hypoglycemic agent decrease blood sugar levels.